See Article page 83.

Commentary: Going beyond the septum for complete repair of obstructive hypertrophic cardiomyopathy

David Blitzer, MD, Stephanie Nguyen, MD, and Hiroo Takayama, MD, PhD

Structural abnormalities of the mitral valve (MV) are commonly seen in conjunction with hypertrophic cardiomyopathy (HCM).¹ Among them, anomalies of the papillary muscles (PMs), first described in 1969, are identified in 13% to 15.4% of patients with HCM.²⁻⁴ Some authors advocate for surgical intervention on the PMs as an adjunct to septal myectomy.⁵ However, there has not been organized knowledge or a systematic approach to this entity until Carvalho and colleagues⁶ published their experience in this issue of the *Journal*.

The authors examined a subset of their patients who underwent myectomy (2.3% of the total experience) consisting of patients with anomalous PMs, defined as direct insertion of PMs into the anterior MV leaflet. The authors demonstrated that anomalous PMs are often associated with concomitant MV pathology requiring additional intervention and that anomalous PMs are often undiagnosed or unrecognized on preoperative or even intraoperative imaging, with just 11% of preoperative transthoracic echocardiograms and 27.4% of intraoperative transesophageal echocardiograms recognizing this pathology. Furthermore, the authors proposed a classification system with 3 distinct patterns of anomalous PM insertion, which further highlights the morphologic complexity of HCM and has important implications in management.

In the current era, transcatheter approaches are encroaching on the territory of the surgeon in the management of

Virtual editorial meeting in the midst of the COVID-19 pandemic.

CENTRAL MESSAGE

Repair of hypertrophic cardiomyopathy may require the surgeon to go beyond a septal myectomy; a systematic approach to anomalies of the mitral valve apparatus is imperative.

HCM. Although HCM may be a niche in surgery, mounting evidence on the important role of nonseptal anatomical causes of obstruction emphasizes the important role of surgical intervention to eliminate the gradient and ensure symptomatic relief for patients.^{1,4}

Appropriate management of MV pathology during septal myectomy is critical to maintaining excellent outcomes, and in most cases of anomalous PMs, will require intraoperative recognition, given the low sensitivity of preoperative imaging. Our group has previously demonstrated that surgical expertise is an important factor in outcomes from septal myectomy, particularly as it relates to the MV.⁷ The impact of MV procedures, especially MV replacement, during septal myectomy has been associated with increasing morbidity and mortality and should only be considered in experienced hands.⁸

We should not forget the principle of this operation: an isolated septal myectomy is (almost) always sufficient in eliminating left ventricular outflow tract obstruction and systolic anterior motion for obstructive HCM. However, recognition and correction of “HCM-associated mitral anomalies” has become an essential component of this operation, going hand-in-hand with septal myectomy. Whether MV repair is a separate procedure is up for debate and may be a mere technicality in the nomenclature. Perhaps “septal myectomy” may no longer be a sufficient term for this operation. It is rather “a repair of obstructive

From the Department of Surgery, Columbia University, New York, NY.

Disclosures: The authors reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

Received for publication April 10, 2020; accepted for publication April 11, 2020; available ahead of print April 21, 2020.

Address for reprints: Hiroo Takayama, MD, PhD, 177 Ft. Washington Ave, Milstein Building 7GN, New York, NY 10032 (E-mail: ht2225@cumc.columbia.edu).

J Thorac Cardiovasc Surg 2022;163:90-1

0022-5223/\$36.00

Copyright © 2020 by The American Association for Thoracic Surgery

<https://doi.org/10.1016/j.jtcvs.2020.04.047>

HCM” and, as such, it is inherently different from alcohol septal ablation.

Carvalho and colleagues from Mayo Clinic, which has an unparalleled track record of providing deep insights on HCM, contributed again by adding another layer of knowledge in this entity. Their experience with these patients is enviable, and in sharing their work in classifying the relevant surgical anatomy and refining surgical technique, they make surgical expertise accessible to the whole field.

References

1. Sherrid MV, Balam S, Kim B, Axel L, Swistel DG. The mitral valve in obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2016;67:1846-58.
2. Wigle ED, Adelman AG, Auger P, Marquis Y. Mitral regurgitation in muscular subaortic stenosis. *Am J Cardiol*. 1969;24:698-706.
3. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. *Circulation*. 1991;84:1188-97.
4. Minakata K, Dearani JA, Schaff HV, O’Leary PW, Ommen SR, Danielson GK. Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy. *Ann Thorac Surg*. 2005;80:851-6.
5. Sigwart U, Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. *Circulation*. 1999;100:e99.
6. Carvalho JL, Schaff HV, Morris C, Nishimura RA, Ommen S, Maleszewski JJ, et al. Anomalous papillary muscles—implications in the surgical treatment of hypertrophic obstructive cardiomyopathy. *J Thorac Cardiovasc Surg*. 2022;163:83-9.e1.
7. Polanco AR, D’Angelo A, Shea N, Yu SN, Chiang YP, Shimada Y, et al. Impact of septal myectomy volume on mitral-valve replacement rate in hypertrophic cardiomyopathy patients. *Cardiology*. 2020;145:161-7.
8. Holst KA, Hanson KT, Ommen SR, Nishimura RA, Habermann EB, Schaff HV. Septal myectomy in hypertrophic cardiomyopathy: national outcomes of concomitant mitral surgery. *Mayo Clin Proc*. 2019;94:66-73.

See Article page 83.

Commentary: Sharing a wealth of information: HOCM surgery

Patrick M. McCarthy, MD

Some may believe that the only road to “truth” is through randomized clinical trials. However, this report of the incredible experience with surgery for hypertrophic obstructive cardiomyopathy (HOCM) at the Mayo Clinic once again highlights the power of extensive clinical experience in the hands, and minds, of expert clinical surgeons who have had the discipline to collect, analyze, and report their experience so that other surgeons can learn.¹ Our specialty has learned much from the fruits of this approach, such as Dr Fred Loop’s report on the superiority of the left internal thoracic artery over saphenous vein grafts for left anterior descending artery bypass and Dr Alain Carpentier’s report of

Patrick M. McCarthy, MD

CENTRAL MESSAGE

Anomalous papillary muscles that insert into the anterior mitral leaflet in patients with hypertrophic myopathy might not be detected before surgery and can benefit from this approach to successful surgery.

the “French correction” for mitral valve repair.^{2,3} The Mayo Clinic reports with HOCM surgery are contributions along the same historic path for this rare disease that even high-volume surgeons might not see often.^{1,4,5}

The Mayo authors identified the presence of accessory papillary muscles in 228 of 3186 patients (7.2%) undergoing myectomy for HOCM, 73 of whom (2.3%) had insertion into the anterior mitral leaflet and were classified into 3 types occurring in almost equal frequency. The article is

From the Cardiac Surgery Division, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Ill.

Disclosures: The author reports receiving speaking fees and royalties from Edwards Lifesciences and speaking fees from Medtronic and AtriCure, and serving as the surgical primary investigator on the REPAIR-MR Trial for Abbott Laboratories.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

Received for publication April 27, 2020; revisions received April 27, 2020; accepted for publication April 28, 2020; available ahead of print May 11, 2020.

Address for reprints: Patrick M. McCarthy, MD, Cardiac Surgery Division, Department of Surgery, Northwestern University Feinberg School of Medicine, 201 East Huron St, Suite 11-140, Chicago, IL 60611-2908 (E-mail: pmccart@nmh.org).

J Thorac Cardiovasc Surg 2022;163:91-2

0022-5223/\$36.00

Copyright © 2020 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery

<https://doi.org/10.1016/j.jtcvs.2020.04.134>